Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: A 5-Year prospective study

Virology Journal

Volumn 8, Issue , 2011, Pages

  Lu, Hui ^a,b   Geng, Da ^a   Shen, Fei ^a   Zhang, Jing ^a   Lu, Bing ^c   Ma, Li ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adefovir Dipivoxil; chronic; hepatitis B; hepatitis B virus; hepatitis Be antigen positive; predictor; therapy

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; PHOSPHONIC ACID DERIVATIVE;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MALE; PROSPECTIVE STUDY; REVIEW; SEROCONVERSION; SEROLOGY; TREATMENT OUTCOME; ARTICLE; CHINA; DRUG EFFECT; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; METABOLISM; VIROLOGY;

HEPATITIS B VIRUS;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHINA; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80053172569     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-444     Document Type: Review

References (26)

1. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, N Engl J Med 2003 348 808 816 10.1056/NEJMoa020681 12606735 (Pubitemid 36245757)
2. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P, Chang TT, Lim S, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F, Hepatology 2008 48 750 758 10.1002/hep.22414 18752330
3. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M, Hepatology 2008 47 2 428 434 10.1002/hep.22065 18220290 (Pubitemid 351280710)
4. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Chien RN, Liaw YF, Atkins M, Hepatology 1999 30 3 770 774 10.1002/hep.510300313 10462384 (Pubitemid 29409422)
5. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Liaw YF, Antivir Ther 2009 14 13 22 19320233
6. Predicting response to peginterferon alpha-2a, lamivudine and the two Combined for HBeAg-negative chronic hepatitis B. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P, Gut 2007 56 699 705 10.1136/gut.2005.089722 17127704 (Pubitemid 46662938)
7. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group, Engl J Med 2005 352 26 2682 2695 10.1056/NEJMoa043470 (Pubitemid 41007823)
8. A pilot study of extended duration of peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Gish RG, Lau DT, Schmid P, Perrillo R, Am J Gastroenterol 2007 102 2718 2723 10.1111/j.1572-0241.2007. 01449.x 17662102 (Pubitemid 350179320)
9. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, Chutaputti A, Rasenack J, Hou J, O'Brien C, Nguyen TT, Jia J, Poynard T, Belanger B, Bao W, Naoumov NV, J Hepatol 2009 51 1 11 20 10.1016/j.jhep.2008.12.019 19345439
10. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL, Antivir Ther 14 679 685
11. Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48. Llop E, De la Revilla J, Pons F, Pẽas B, Martínez JL, Abreu L, Calleja JL, Rev Asp Enferm Dig 2009 101 11 763 767
12. Chronic hepatitis B: update 2009. Lok AS, McMahon BJ, Hepatology 2009 50 3 661 662 10.1002/hep.23190 19714720
13. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C, Hepatology 2007 46 254 265 10.1002/hep.21698 17596850 (Pubitemid 47171942)
14. Invitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Qi X, Xiong S, Yang H, Miller M, Delaney WE, Antivir Ther 2007 12 355 362 17591025 (Pubitemid 46787980)
15. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, Janssen HL, J Viral Hepat 2009 16 113 120 10.1111/j.1365-2893.2008.01053.x 19175883
16. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B. The GLOBE study. Zeuzem S, Buti M, Gane EJ, Hepatology 2007 46 Suppl 1 681 A
17. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Yuen M-F, Yuan H-J, Hui C-K, Wong D-K, Wong WM, Chan AO, Wong BC, Lai CL, Gut 2003 52 3 416 419 10.1136/gut.52.3.416 12584226 (Pubitemid 36250064)
18. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y, Adefovir Dipivoxil 437 and 438 Study Groups, J Viral Hepat 2009 16 3 203 213 10.1111/j.1365-2893.2008.01065.x 19175871
19. Lamivudine for patients with chronic hepatitis B and advanced liver disease. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group, N Engl J Med 2004 351 15 1521 1531 10.1056/NEJMoa033364 15470215 (Pubitemid 39315319)
20. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M, Asian-Pacific consensus update working party on chronic hepatitis B, Liver Int 2005 25 3 472 489 10.1111/j.1478-3231.2005.01134.x 15910483 (Pubitemid 40861895)
21. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, David E, Verme G, Bonino F, Hepatology 1989 10 2 198 202 10.1002/hep.1840100213 2663695 (Pubitemid 19190211)
22. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF, Am J Med 2004 116 12 829 834 10.1016/j.amjmed.2003.12.040 15178498 (Pubitemid 38721324)
23. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA, Hepatology 2010 51 6 1933 1944 10.1002/hep.23571 20512987
24. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P, Hepatology 2009 49 4 1141 1150 10.1002/hep.22760 19338056
25. HBV DNA level as an important determinant of e antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy. Tseng KC, Cheng PN, Wu IC, Chang CK, Chou AL, Liu WC, Chang TT, Hepatogastroenterology 2009 56 91-92 813 818 19621708
26. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Clin Gastroenterol Hepatol 2008 6 12 1315 1341 quiz 1286 10.1016/j.cgh.2008.08.021 18845489